Pair page
Syn-Ake with Vialox
Mechanism-tag overlap and published literature for Syn-Ake and Vialox, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
cosmetic-snake-venom-mimetic
cosmetic-neuromuscular-inhibitor
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Syn-Ake and Vialox have published these mechanism-level observations. Not a co-administration recommendation.
Another nAChR-antagonist cosmetic peptide marketed by Centerchem with a similar "muscle-relaxing" mechanistic claim. Stacks naturally with Syn-Ake at the "postsynaptic nAChR antagonism" mechanism level. Typical combined use: 2% Vialox + 2% Syn-Ake solution.
A synthetic tripeptide derivative inspired by waglerin-1 from temple pit viper venom — also a postsynaptic muscle nAChR antagonist. Mechanism overlaps with Vialox's claimed pharmacology but with a different molecular architecture. Frequently bundled with Vialox in finished cosmetic products.
Quick facts
Syn-Ake
Vialox
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2012 | Syn-Ake | Beer K, Waibel J. Botulinum toxin type A enhances the duration of clinical effect of topically applied Acetyl Hexapeptide-8 in patients with blepharospasm. (Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of Blepharospasm in Patients Receiving Botulinum Neurotoxin Thera… | human pilot |
| 1995 | Syn-Ake | Tsai MC, Hsieh WH, Smith LA, Lee CY. Effects of waglerin-I on neuromuscular transmission of mouse nerve-muscle preparations. Toxicon. 1995;33(3):363-371. PMID: 7638875. PMID 7638875 | preclinical, in vivo |
| 1992 | Syn-Ake | Aiken SP, Sellin LC, Schmidt JJ, Weinstein SA, McArdle JJ. A novel peptide toxin from Trimeresurus wagleri acts pre- and post-synaptically to block transmission at the rat neuromuscular junction. Pharmacol Toxicol. 1992;70(6 Pt 1):459-462. PMID: 1359525. PMID 1359525 | preclinical, in vivo |
| 1991 | Syn-Ake | Weinstein SA, Schmidt JJ, Bernheimer AW, Smith LA. Characterization and amino acid sequences of two lethal peptides isolated from venom of Wagler's pit viper, Trimeresurus wagleri. Toxicon. 1991;29(2):227-236. PMID: 2048140. PMID 2048140 | mechanism / discovery |
| 2025 | Syn-Ake | Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Cosmetics. 2025; PMC12193160. (Recent review of the most-studied class analog, evaluating skin permeation barriers — directly applicable to interpreting realistic Syn-Ake efficacy ceilings.) | review |
| 2022 | Syn-Ake | Anti-ageing peptides and proteins for topical applications: a review. Pharm Dev Technol. 2022;27(1):108-125. PMID: 34957891. (Recent comprehensive review of topical anti-aging peptides including discussion of nAChR-antagonist class members.) PMID 34957891 | review |
| — | Syn-Ake | Wikipedia / scholarly venomic summary: Tropidolaemus wagleri . Note: While T. wagleri 's waglerin-1 selectively blocks the ε-subunit-containing acetylcholine receptor of adult muscle, there is no scientific evidence supporting the manufacturer claim that the much smaller Syn-Ake… | industry documentation |
| 2005 | Syn-Ake | Lupo MP. Cosmeceutical peptides. Dermatol Surg. 2005;31(7 Pt 2):832-836. PMID: 16029675. PMID 16029675 | research article |
| 2002 | Syn-Ake | Molles BE, Tsigelny I, Nguyen PD, Gao SX, Sine SM, Taylor P. Residues in the epsilon subunit of the nicotinic acetylcholine receptor interact to confer selectivity of waglerin-1 for the alpha-epsilon subunit interface site. Biochemistry. 2002;41(25):7895-7906. PMID: 12069578. PMID 12069578 | research article |
| 2002 | Syn-Ake | Molles BE, Rezai P, Kline EF, McArdle JJ, Sine SM, Taylor P. Identification of residues at the alpha and epsilon subunit interfaces mediating species selectivity of Waglerin-1 for nicotinic acetylcholine receptors. J Biol Chem. 2002;277(7):5433-5440. PMID: 11724791. PMID 11724791 | research article |
| 2002 | Syn-Ake | Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. PMID: 18498523. (The pivotal cosmetic-peptide reference… PMID 18498523 | research article |
| 1999 | Syn-Ake | McArdle JJ, Lentz TL, Witzemann V, Schwarz H, Weinstein SA, Schmidt JJ. Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 1999;289(1):543-550. PMID: 10087048. (The pivotal paper establishing waglerin-1's selectiv… PMID 10087048 | research article |
| 2025 | Vialox | Mlosek RK, Migda B, Skrzypek E, Słoboda K, Migda M. Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025. PMID: 40565185. (2025 systematic review of permeability and efficacy for the closest mechanistic neighbor to Vialox.) PMID 40565185 | systematic review |
| 2013 | Vialox | Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147-153. doi:10.1007/s40257-013-0009-9. PMID: 23417317. (Randomized placebo-c… PMID 23417317 | human trial |
| 2017 | Vialox | Tan CH, Tan KY, Yap MK, Tan NH. Venomics of Tropidolaemus wagleri, the sexually dimorphic temple pit viper: Unveiling a deeply conserved atypical toxin arsenal. Sci Rep. 2017;7:43237. doi:10.1038/srep43237. (Modern venomics characterization of the temple pit viper venom containi… | mechanism / discovery |
| 1991 | Vialox | Weinstein SA, Schmidt JJ, Bernheimer AW, Smith LA. Characterization and amino acid sequences of two lethal peptides isolated from venom of Wagler's pit viper, Trimeresurus wagleri. Toxicon. 1991;29(2):227-236. doi:10.1016/0041-0101(91)90107-3. (Original characterization of the w… | mechanism / discovery |
| 2017 | Vialox | Pai VV, Bhandari P, Shukla P. Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 2017;83(1):9-18. doi:10.4103/0378-6323.186500. PMID: 27451932. (2017 review of cosmetic peptides including discussion of neurotransmitter inhibitors and curare-mimetic peptides.) PMID 27451932 | review |
| 2017 | Vialox | Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016. (MDPI Cosmetics review of the cosmetic-peptide landscape including Pentapeptide-3 / Vialox; not PubMed-indexed but widely cited.) | review |
| 2018 | Vialox | DSM Personal Care / Pentapharm. Pentapeptide-3 (Vialox PT) — Product Brochure. Basel, Switzerland: DSM; 2018 (and subsequent revisions). (Manufacturer brochure documenting Pentapharm in-house clinical evaluation methodology; the underlying source of the "49% wrinkle reduction" h… | industry documentation |
| 2017 | Vialox | Centerchem Inc. Vialox® Pentapeptide-3 — Technical Data Sheet. Norwalk, CT: Centerchem; 2017 (and subsequent technical bulletins). (Primary manufacturer technical literature describing in-vitro and in-vivo claims; cited here as the documented source of widely repeated wrinkle-re… | industry documentation |
| 2015 | Vialox | Hoppel M, Reznicek G, Kählig H, Kotisch H, Resch GP, Valenta C. Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure. Eur J Pharm Sci. 2015;68:27-35. doi:10.1016/j.ejps.2014.11.014. PMID: 25497319. (The most… PMID 25497319 | research article |
| 2015 | Vialox | Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26050778. (Reference for the major cosmetic carrier peptide commonly stacked with V… PMID 26050778 | research article |
| 2010 | Vialox | Reszko AE, Berson D, Lupo MP. Cosmeceuticals: practical applications. Obstet Gynecol Clin North Am. 2010;37(4):547-569,viii. doi:10.1016/j.ogc.2010.09.006. PMID: 21093749. (Practical clinical-dermatology overview of cosmeceutical peptide categories with reference to Vialox-class… PMID 21093749 | research article |
| 2007 | Vialox | Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. doi:10.1111/j.1529-8019.2007.00148.x. PMID: 18045359. (Widely cited dermatology review that catalogues Pentapeptide-3 / Vialox alongside Argireline as neurotransmitter-affecting cosmetic peptides.) PMID 18045359 | research article |
Related pair pages
More research context
Frequently asked
Have Syn-Ake and Vialox been studied together?
Researchers have published mechanistic-level co-administration discussion of Syn-Ake and Vialox. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Syn-Ake and Vialox share?
Syn-Ake and Vialox do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Syn-Ake and Vialox?
Syn-Ake: Cosmetic ingredient (not drug-approved). Vialox: Cosmetic ingredient (not a drug). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Syn-Ake and Vialox?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Syn-Ake profile and the Vialox profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026